Siddharth Negandhi

“You mentioned that... Ex-oncology growth is 25% in revenue. Could you help me understand what would that also mean in terms of EBITDA growth?”

“First up, considering your guidance of the upper end of your guidance of 12% growth with 35% margins, right? 35-36% margins. So, both on the upper end leaves us with about 13% growth and 33% margins for the second half.”

“Just wanted to clarify on how much is the CDMO revenue and what's the status in terms of user CDMO contracts? Last quarter, you mentioned about $2 million in revenue.”

“On the pharma intermediates business, you mentioned that CDMO could achieve 1,000 crores on FI 27th. Could you help us understand how much of that is already in the bag in H1, which is your pharma intermediates business, the innovator and generic split?”

“One, the rate of approval seems to be marginally slowing down, while revenue growth obviously continues at a very, very healthy pace. Is this a fewer, bigger strategy now?”